The FinTech Hub
Source: Live Mint Pharma Stocks; Indian Pharma market grew a a healthy 9.3% year on year during the month of March’2025 suggest reports. Cipla, Sun Pharmaceutical Industries, Ipca Laboratories Ltd, JB Chemicals & Pharmaceuticals Ltd (JB Pharma), Glenmark Pharmaceuticals Ltd were the key drivers of Indian pharma market growth during the month of March’2025. Pharma…
Source: Live Mint JD Sports gains on forecasting in line annual profitability UK 30-year gilt yields surge FTSE 100 down 2.9%, FTSE 250 fell 2.5% British stocks ended lower on Wednesday, dragged by heavyweight pharmaceutical stocks, while markets remained focused on tariff escalations between the U.S. and China. The blue-chip FTSE 100 slipped 2.9%, after…
Source: Live Mint The Nifty 50 fell 1.5% to close at 22,904.45 while the Sensex dropped 1.2%, ending at 75,364.69. The smaller shares took a bigger hit, with Nifty Midcap 100 tumbling 2.9% and Nifty Smallcap 250 plunging 3.3%. Elsewhere, Hong Kong’s Hang Seng, China’s Shanghai Composite, Japan’s Nikkei and South Korea’s Kospi fell 1.5%,…
Source: Live Mint Stock market today: Indian markets kicked off FY26 on a somber note, tracking the sharp sell-off in U.S. markets overnight after U.S. President Donald Trump on Sunday, said tariffs would essentially cover all countries, stoking worries a global trade war could lead to a recession. Investors had been hoping for a more…
Source: Live Mint Sun Pharmaceutical Industries Ltd. has announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company, in a $355 million cash deal. The acquisition will bolster Sun Pharma’s onco-dermatology portfolio, adding Checkpoint’s recently FDA-approved cancer drug, UNLOXCYT (cosibelimab-ipdl), to its pipeline. The deal, expected to close in the second…
Source: Live Mint Shares of pharma major Lupin rebounded from their day’s low after the company posted strong financial results for the quarter ended December 2024 (Q3 FY25). The stock initially fell by 3.2 percent to an intra-day low of ₹2,000.10 in early trade but later recovered by almost 6 percent, reaching day’s high of…
Source: Live Mint Budget 2025: Pharma stocks experienced a mixed trading session on Saturday following Finance Minister Nirmala Sitharaman’s declaration of exemptions from basic customs duty (BCD) for 36 essential medications. Additionally, six life-saving drugs will only incur a reduced duty rate. “I propose to add 36 lifesaving drugs and medicines to the list of…
Source: Live Mint Stocks of Indian pharma companies supplying antiretroviral (ARV) medicines used to treat HIV to African countries tumbled on Monday after a US government order halted all foreign aid funding, including its AIDS relief program. On January 25, the US State Department put into action an executive order from President Donald Trump halting…
Source: Live Mint The Indian pharma industry is likely to grow at 9-11% in FY26 (as per Crisil Report), led by price hike and new launches in domestic market and rise in export demand from regulated markets. The Government of India has introduced PLI scheme for pharma industry to promote Make-in-India, wherein ~18-20% of imported…
Source: Live Mint Market outlook: The Indian equity markets remained resilient for a major part of the calendar year (CY) 2024, despite challenges posed by sticky inflation, weaker-than-expected Q2FY25 earnings, general election outcomes, FII outflows, and geopolitical uncertainty. Despite these headwinds, India’s benchmark indices, the Nifty 50 and Sensex, delivered positive returns of 11.35% and…
